# A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

> **NCT07687602** · — · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 69 (estimated)

## Conditions studied

- Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer
- Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer
- Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07687602
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687602, "A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*